INKT

MiNK Therapeutics, Inc. (NASDAQ:INKT) is a clinical-stage biopharmaceutical company founded in 2017 and based in New York, New York. Originally incorporated as AgenTus Therapeutics, Inc., the company went public in October 2021 and operates as a subsidiary of Agenus Inc. MiNK specializes in developing innovative cancer immunotherapies using a unique type of immune cell called invariant natural killer T (iNKT) cells, positioning itself at the forefront of next-generation cell therapy development.